June 5, 2023. An impressive stride in the biotech industry is made as Enzolytics, Inc. – a pioneer in drug development and a beacon of hope for debilitating infectious diseases – shares updates about the sale of its wholly-owned subsidiaries, Virogentics, Inc. and Biogenysis, Inc., as well as details regarding its ongoing clinical trials approved by the European Medicine Agency (EMA) and the Arican ITV-1 project.
Spurring Change in Biotech: The Sale of Virogentics and Biogenysis
Setting a milestone, Enzolytics is facilitating the sale of its subsidiaries, Virogentics (“VIRO”) and Biogenysis (“BGEN”), to Sagaliam Acquisition Corp (SAGA:NASDAQ GM), a special purpose acquisition company (“SPAC”). The transaction is on its way to completion, pending final negotiations between BN Holdings Trust and the existing sponsor of SAGA and certain regulatory filings. Although Enzolytics is not directly involved in the negotiations or filings, the company is closely monitoring the progress of this transformative deal.
European Medicine Agency Clinical Trials Progress
Enzolytics is also gearing up its advancements in clinical trials, with a recent comprehensive report from the Bulgarian Academy of Sciences setting the groundwork for the ITV-1 project. Notably, this report revealed that the protein concentration in the final ITV-1 product was found to be adequately high for effective activity. With this research dossier, Enzolytics is confidently prepping for the Phase 3 clinical trials under the EMA guidelines, indicating a major step forward in its efforts.
In partnership with Germany’s Cooperative Clinical Research and Development, preparations for a Pharmacokinetic study on porcine pepsin are underway, scheduled to commence on June 25, 2023.
Arican ITV-1 Project: A Hopeful Leap in Immunotherapy
In collaboration with Neuro Pharma Ltd – Rwanda, Enzolytics is making waves in its ITV-1 immunotherapy treatment, which is set to be administered to volunteers under a fast-track protocol at HEAL Africa Hospitals and Panzi Hospital. With an expected launch in late July or early August 2023, this treatment’s impact on the HIV/AIDS virus in the volunteers will be closely tracked and reported upon completion of the 17-week cycle.
Harry Zhabilov, CSO of VIRO, proudly remarks on these significant developments, “We are very fortunate to have successfully completed these steps in these projects and look forward to the continued success from the ENZC’s team efforts.”
A Look at Enzolytics
As a trailblazer in the drug development industry, Enzolytics, Inc. is resolute in its mission to commercialize proprietary proteins and monoclonal antibodies to battle debilitating infectious diseases. With one patented and clinically tested compound, ITV-1, which has shown promising results in treating HIV/AIDS, Enzolytics stands at the forefront of biotech innovation. Its proprietary technology for producing fully human monoclonal antibodies (mAbs) positions it to potentially revolutionize the treatment landscape for several infectious diseases, including SARS-CoV-2, HIV-1, and the Feline Leukemia virus.
Although the future of Enzolytics’ therapeutics in the treatment of various diseases shows potential, there are inherent risks and uncertainties involved. These include the successful outcome of clinical trials, the achievement of funding, and the completion of studies and tests. While the company holds an optimistic outlook, it recognizes that the accuracy of forward-looking statements may vary based on these factors.
Enzolytics continues to keep its vision unfaltering and is determined to make valuable contributions to the world of infectious disease treatment. It relentlessly pursues the development of its proprietary technology and clinical trials, paving the way for a future where debilitating diseases can be effectively combated.
A Safe Harbor Statement has been issued by Enzolytics, Inc., emphasizing that the forward-looking statements made in this press release are based on current expectations and assumptions, and are accompanied by uncertainties and risks that could lead to discrepancies in the actual outcomes.
In spite of the uncertainties, the company believes in the power of innovation and the immense potential of its therapeutics. Harry Zhabilov, CSO of VIRO, sums up the spirit of the company perfectly, “We are very fortunate to have successfully completed these steps in these projects and look forward to the continued success from the ENZC’s team efforts.”
While keeping a realistic view of the risks involved, Enzolytics’ unwavering dedication and progress signify a promising future for the biotech industry and the ongoing battle against infectious diseases.
Stay updated with the latest advancements and breakthroughs from Enzolytics by visiting www.enzolytics.com.
Company Contact:
Enzolytics, Inc. 1101 Raintree Circle Allen, Texas 75013 www.enzolytics.com
SOURCE: Enzolytics, Inc.
§
Disclaimer: The information provided in this response is for general informational purposes only and should not be construed as investment advice, financial guidance, an offer or solicitation to buy or sell any securities, or a recommendation for any specific investment or financial strategy. Investing involves risks, including the potential loss of principal. You should always conduct your own research, consult with a qualified financial professional, and consider your individual circumstances, financial goals, and risk tolerance before making any investment decisions. Past performance is not indicative of future results, and no guarantees can be made about the success or outcome of any investment strategy.